CBR Seminar: Facioscapulohumeral Muscular Dystrophy Event as iCalendar

14 September 2017

10 - 11:30am

Venue: Clinical Education Centre

Location: Auckland City Hospital

Host: Miriam Rodrigues

Contact info: Frankie Favero

Contact email: f.favero@auckland.ac.nz

CBR  banner ADHB 2

 

Facioscapulohumeral Muscular Dystrophy

 

Scott Q Harper, PhD

Scott Harper is an Associate Professor of Pediatrics at The Ohio State University College of Medicine and Principal Investigator in the Center for Gene Therapy at the Research Institute at Nationwide Children’s Hospital, in Columbus, Ohio, USA.

From 1996 to 2002, Dr. Harper earned a PhD in Cellular and Molecular Biology from the University of Michigan, where he worked on developing gene therapy approaches to treat Duchenne Muscular Dystrophy (DMD).  Following that, from 2002 – 2007, he trained as a post-doctoral fellow at the University of Iowa.  During this time, a new field of biology – gene silencing – was emerging, and Dr. Harper worked to develop gene silencing techniques to treat dominant brain diseases, including Huntington’s Disease (HD). 

In 2007, Dr. Harper started his own laboratory with the goal to combine his two areas of training – gene therapy for muscular dystrophy and gene silencing strategies – and develop a new research program in an area that had long been understudied:  FSHD.  During the last decade, the Harper lab has been working to create models of FSHD and develop therapies for the disease.

 

Paul Gregorevic, PhD

Dr Gregorevic gained his PhD from the University of Melbourne in 2001. He subsequently trained as a postdoctoral research fellow within the University of Washington Department of Neurology, Seattle USA, where he acquired expertise in molecular biology and the design of recombinant viral vectors as gene delivery technologies for studying and treating muscle diseases. In 2008,

Dr Gregorevic relocated his research program to the Baker Heart and Diabetes Institute, Melbourne, where he is Head of the Laboratory for Muscle Biology and Therapeutics Development, and Director of the Recombinant Viral Vector Core. His research interests focus on elucidating the mechanisms underlying the development and regulation of the skeletal muscle phenotype, and the development of novel therapeutic interventions to combat loss of muscle function associated with heritable and acquired diseases, and the aging process. 

 

Alice Theadom, PhD

Alice is a Registered Psychologist, specialising in understanding how people adjust to neurological illness and injury. She is widely experienced in conducting epidemiological studies to determine disease burden, running clinical trials of non-pharmacological interventions in addition to qualitative studies to understand the illness experience. She is a member of the Global Burden of Disease Project which aims to determine the worldwide burden of injury and illness as well as the CENTER-TBI international collaboration on traumatic brain injury funded by the EU Commission.

Alice has attracted >5million in external research funding in the last 5 years and has published >85 peer-reviewed journal articles including The Lancet and Lancet Neurology. Alice is Assistant Editor for the Journal Neuroepidemiology and is an editorial board member for the journal, Brain Impairment.

Alice teaches on applying psychological principles in neurorehabilitation, evaluating the use of outcome measures in clinical practice and has developed a new postgraduate training programme in Rehabilitation Psychology. She was the Principal Investigator of the Prevalence of Genetic Muscle Disorders (MD-Prev) study funded by the Health Research Council of New Zealand, from which the data for this study looking at the impact of FSHD was extracted.